Compare American Tower Corp (AMT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Tower Corp vs BIO-TECHNE Corp — how do they compare? American Tower Corp trades at $169.8 (market cap $78.80B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: American Tower Corp is far larger — about 7× BIO-TECHNE Corp's market cap, and American Tower Corp pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| AMT | TECH | |
|---|---|---|
Market Cap | $78.80B | $11.24B |
Sector | Real Estate | Health |
52-Week High | $211.88 | $72.29 |
52-Week Low | $162.11 | $43.31 |
Enterprise Value | $122.32B | $11.32B |
Dividend Yield | 4.13% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Tower (AMT) trades at $172.54, up 0.78% on the day, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.86 exceeding the $1.57 forecast. Revenue for 2025 reached $10.64 billion, with a robust net income margin of 26.81%. Analyst sentiment is overwhelmingly positive, with 39 of 49 analysts rating it a Buy and a consensus price target of $206.17, implying significant upside. Recent news highlights insider selling and upbeat analyst coverage.
The outlook for AMT is favorable, driven by resilient telecom demand, 5G/6G expansion, and double-digit growth in its data center segment. Key risks include sensitivity to interest rates, Dish Network churn impacts, and high debt levels. With strong cash flow from operations and a bullish analyst consensus, the stock presents a compelling opportunity for growth-oriented investors, though macroeconomic factors warrant monitoring.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Tower Corp
American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.
Read more on AMT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
